Kintor Pharmaceutical Ltd is an investment holding company primarily engaged in the research and development of innovative medicine products. The Company's products are dedicated to addressing disease areas that have not met clinical needs, and its pipeline mainly covers indications of dermatology (such as androgenetic alopecia, acne vulgaris) and indications of tumors. The Company has two core drugs in the dermatology field, KX-826 and GT20029. The Company's other disease areas include metastatic castration-resistant prostate cancer (mCRPC), liver cancer, idiopathic pulmonary fibrosis, malignant blood diseases and various solid tumors.

Employees

123

Sector

Biotechnology & Medical Research

More about the company

Income Statement and Estimates

More financial data

Annual profits - Rate of surprise

Company calendar

Market Closed - OTC Markets Other stock markets 21:30:00 15/06/2026 HKT			5-day change	1st Jan Change
0.3420 ^USD	+22.10%		0.00%	+58.33%

06-11	Kintor Pharma Posts Positive Interim Safety Data for Whitening Agent KT-939	MT
06-10	Kintor Pharmaceutical Limited Announces Positive Interim Result in Long-Term Human Safety Trial of Kt-939 and Commences Registration Application for New Raw Material	CI

Market Cap	792M 116M 102M 94.15M 88.15M 165M 10.99B 169M 1.13B 438M 5.43B 437M 428M 18.83B	P/E 2024	-2.53x	P/E 2025	-3.96x
Enterprise Value	846M 124M 109M 101M 94.14M 177M 11.74B 180M 1.21B 468M 5.8B 467M 457M 20.11B	EV / Sales 2024	75,794,130x	EV / Sales 2025	28,245,180x
Free-Float	83.1%	Yield 2024 *	-	Yield 2025	-

06-11	Kintor Pharma Posts Positive Interim Safety Data for Whitening Agent KT-939	MT
06-10	Kintor Pharmaceutical Limited Announces Positive Interim Result in Long-Term Human Safety Trial of Kt-939 and Commences Registration Application for New Raw Material	CI
05-28	Kintor pharmaceutical says CEO via wholly owned co increases shareholding by 2.51 million shares	RE
05-27	Kintor Pharmaceutical Auditor to Retire; Shares Drop 7%	MT
05-26	Kintor Pharmaceutical Limited Announces Change of Address of Principal Place of Business in Hong Kong, with Effect from 1 June 2026	CI
04-21	Kintor Pharmaceutical's 2026 Sales Jump Past 2025 Full-Year Level	MT
04-21	Kintor Pharmaceutical says ytd 2026 sales revenue at RMB34 million	RE
04-20	Kintor Pharmaceutical Limited Provides Sales Guidance for the Year 2026	CI
04-20	Kintor Pharmaceutical Limited Announces Preliminary Sales Results for the Year to Date Ended April 20, 2026	CI
03-30	Kintor Pharmaceutical Limited Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-19	Kintor Pharma's Androgenetic Alopecia Drug Meets Primary Endpoint in Phase 3 Trial; Shares Plunge 21%	MT
03-18	Kintor pharmaceutical says pharma's KX-826 phase III trial in China reaches primary endpoint	RE
03-18	Kintor Pharmaceutical Limited Announces Phase III Clinical Trial Results For KX-826 Tincture 1.0% For Male Adult AGA In China	CI

28/10/23	Kintor Pharmaceutical : Pharma Announces Publication of Phase Ib/II Data from GT90001 and Nivolumab Combination Therapy for Advanced HCC in BMC Medicine	PU
11/10/23	Kintor Pharmaceutical : Pharma Announces the Approval of Phase II Clinical Trial of Hedgehog/SMO Inhibitor GT1708F for Treatment of IPF in China	PU
28/08/23	Kintor Pharmaceutical : Pharma Announces 2023 Interim Results and Recent Business Highlights	PU
22/08/23	Kintor Pharmaceutical : Pharma Announces Completion of Patient Enrollment in Phase II Clinical Trial of GT20029 for Treatment of Androgenetic Alopecia in China	PU
20/07/23	Kintor Pharma Announces Completion of First Patient Enrollment in KX-826 Long-term Safety Phase III Trial for Treatment of AGA	AQ

Kintor Pharmaceutical Limited Stock OTC Markets

Stocks

KNTPF

KYG5273B1077

Biotechnology & Medical Research

Valuation: Kintor Pharmaceutical Limited

Chart: Kintor Pharmaceutical Limited

Latest news : Kintor Pharmaceutical Limited

Press Releases: Kintor Pharmaceutical Limited

Quotes and Performance

Course Extremes

Managers and Directors: Kintor Pharmaceutical Limited

Bio Therapeutic Drugs

Financials

Company Profile

Income Statement and Estimates

Annual profits - Rate of surprise

1 day	+22.10%
Current month	+27.42%
1 month	+6.24%
3 months	-20.96%
6 months	+58.33%
Current year	+58.33%

1 month	0.28	0.34
Current year	0.26	0.57
1 year	0.22	0.57
3 years	0.08	0.57
5 years	0.08	11.8
10 years	0.08	11.8

Manager	Title	Age	Since
You Zhi Tong CEO	Chief Executive Officer	64	24/03/2009
Ming Ming Cheung DFI	Director of Finance/CFO	49	14/04/2023
Hong Long Lu CTO	Chief Tech/Sci/R&D Officer	49	01/09/2020

Director	Title	Age	Since
You Zhi Tong CHM	Chairman	64	24/03/2009
Min Xu BRD	Director/Board Member	61	12/08/2019
Yeung Wai Yim BRD	Director/Board Member	62	12/08/2019

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
KINTOR PHARMACEUTICAL LIMITED	+22.10%	0.00%	-	-	116M
ARGENX SE	+0.33%	+1.37%	+63.66%	+126.38%	55.63B
WUXI APPTEC CO., LTD.	+0.82%	+15.05%	+79.52%	+85.53%	52.25B
BIONTECH SE	+1.36%	+0.36%	-14.52%	-13.83%	23.07B
INSMED INCORPORATED	-1.04%	+7.91%	+3.91%	+417.68%	22.41B
WUXI BIOLOGICS (CAYMAN) INC.	-0.18%	+7.20%	+31.37%	-13.62%	17.32B
GENMAB A/S	-1.10%	+4.00%	+29.97%	-33.36%	15.94B
EXELIXIS, INC.	+2.89%	+5.51%	+25.42%	+186.30%	13.77B
PHARMAESSENTIA CORPORATION	-3.35%	+8.96%	+134.32%	+289.59%	13.47B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+1.31%	+0.53%	+27.83%	-	12.43B
Average	+2.31%	+4.78%	+42.39%	+130.58%	25.14B
Weighted average by Cap.	+0.27%	+5.13%	+48.50%	+122.68%

	2024	2025
Net sales	5 0.74 0.64 0.59 0.56 1.04 69.34 1.06 7.14 2.76 34.27 2.76 2.7 118.83	32.68 4.8 4.21 3.88 3.64 6.82 453.21 6.96 46.67 18.06 223.99 18.04 17.65 776.69
Net income	-155M -22.83M -20.02M -18.45M -17.27M -32.39M -2.15B -33.06M -222M -85.81M -1.06B -85.72M -83.85M -3.69B	-200M -29.42M -25.79M -23.77M -22.26M -41.74M -2.77B -42.6M -286M -111M -1.37B -110M -108M -4.76B
Net Debt	-15.68M -2.31M -2.02M -1.86M -1.74M -3.27M -217M -3.34M -22.39M -8.66M -107M -8.66M -8.47M -373M	53.86M 7.92M 6.94M 6.4M 5.99M 11.23M 747M 11.47M 76.91M 29.76M 369M 29.73M 29.08M 1.28B